Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma

American Journal of Surgical Pathology

Volumn 32, Issue 11, 2008, Pages 1699-1708

  Meyronet, David ^a,b,c,d   Massoma, Patrick ^a,b   Thivolet, Françoise ^b,d   Chalabreysse, Lara ^b,d   Rogemond, Véronique ^a,d   Schlama, Aline ^a,c   Honnorat, Jérôme ^a,c,d   Thomasset, Nicole ^a,d  

^a INSERM   (France)

^b Centre de Pathologie et de Neuropathologie Est   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

CRMP5; Diagnostic marker; Lung neoplasm; Neuroendocrine carcinoma

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; TUMOR MARKER; UNCLASSIFIED DRUG; DPYSL5 PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WORLD HEALTH ORGANIZATION; BIOSYNTHESIS; CARCINOMA; DISEASE FREE SURVIVAL; GENE EXPRESSION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CARCINOMA, NEUROENDOCRINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 56149092513     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31817dc37c     Document Type: Article

References (31)

1. American Cancer Society AJCoC. AJCC Cancer Staging Handbook. Secaucus, NJ: Springer; 2002:469.
2. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70-76.
3. Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology. 2004;62:778-782.
4. Bretin S, Reibel S, Charrier E, et al. Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol. 2005;486: 1-17.
5. Camdessanche JP, Lassabliere F, Meyronnet D, et al. Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. J Neuroimmunol. 2006;174:168-173.
6. Charrier E, Reibel S, Rogemond V, et al. Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol. 2003;28:51-64.
7. Chu PG, Arber DA, Weiss LM. Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. Am J Clin Pathol. 2003;120:64-70.
8. Corrin B. Pathology of the Lungs. London: Hartcourt Publishers Limited; 1995:668.
9. Goshima Y, Nakamura F, Strittmatter P, et al. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature. 1995;376:509-514.
10. Honnorat J, Byk T, Kusters I, et al. Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci. 1999;11:4226-4232.
11. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation - an entity of no clinical or prognostic significance. Am J Surg Pathol. 2007;31: 26-32.
12. Ito T, Kagoshima M, Sasaki Y, et al. Repulsive axon guidance molecule Sema3A inhibits branching morphogenesis of fetal mouse lung. Mech Dev. 2000;97:35-45.
13. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004;363: 775-781.
14. Katsetos CD, Kontogeorgos G, Geddes JF, et al. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med. 2000; 124:535-544.
15. Kusy S, Nasarre P, Chan D, et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia. 2005;7:457-465.
16. Matsuki Y, Tanimoto A, Hamada T, et al. Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. Mod Pathol. 2003;16:72-78.
17. Monstad SE, Drivsholm L, Skeie GO, et al. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother. 2007;57:227-232.
18. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26: 1184-1197.
19. Pankiewicz W, Minarowski L, Niklinska W, et al. Immunohistochemical markers of cancerogenesis in the lung. Folia Histochem Cytobiol. 2007;45:65-74.
20. Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29:179-187.
21. Ricard D, Rogemond V, Charrier E, et al. Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/ CRMP2 in Sema3a-sensitive oligodendrocytes. J Neurosci. 2001; 21:7203-7214.
22. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23:8774-8785.
23. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003;123: 259S-271S.
24. Soong R, Beyser K, Basten O, et al. Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res. 2001;7: 3423-3429.
25. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol. 2002; 33:175-182.
26. Sturm N, Rossi G, Lantuejoul S, et al. 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology. 2003;42:156-166.
27. Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 2006;29:567-575.
28. Travis WD. The concept of pulmonary neuroendocrine tumours. In: Travis WD, Brambilla E, Muller-Hermelink KH, et al. Pathology and Genetics of Tumours of the Lung, Pleura Thymus and Heart. Lyon: IARC; 2004:19-20.
29. Veyrac A, Giannetti N, Charrier E, et al. Expression of c ollapsin response mediator proteins 1, 2 and 5 is differentially regulated in newly generated and mature neurons of the adult olfactory system. Eur J Neurosci. 2005;21: 2635-2648.
30. Wang LH, Strittmatter SM. A family of rat CRMP genes is differentially expressed in the nervous system. J Neurosci. 1996;16: 6197-6207.
31. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49:146-154.